Protalix BioTherapeutics, Inc. — Director's Dealing 2012

May 4, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Protalix BioTherapeutics, Inc. (PLX)
CIK: 0001006281
Period of Report: 2012-05-02

Reporting Person: Maimon Yossi (VP, Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-05-02	Common Stock	M	75964	$0.972	Acquired	75964	Indirect
2012-05-02	Common Stock	M	50000	$2.65	Acquired	125964	Indirect
2012-05-02	Common Stock	S	125964	$7.13	Disposed	0	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-05-02	Stock Options (Right to Buy)	$0.972	M	75964	Disposed	2016-09-19	Common Stock (75964)	Direct
2012-05-02	Stock Options (Right to Buy)	$2.65	M	50000	Disposed	2019-02-25	Common Stock (50000)	Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee upon the exercise of stock options must be registered in the name of a trustee.

F3: All options are fully vested.

F4: Does not include (i) options to purchase 175,000 shares of common stock at an exercise price equal to $5.00 per share that expire on February 7, 2018 and (ii) options to purchase 130,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020.